In contrast to the situation observed in mesothelioma and renal clear cell carcinoma (ccRCC), where BAP1 function is commonly affected by mutations [10], in pancreatic cancer, approximately 26% of patients exhibit low expression of BAP1 due to copy number deletions [11]. This evidence concerns the gene BAP1 and nonpapillary renal cell carcinoma.